USPTO Form 1449 Patent and Trademark Office INFORMATION DISCLOSURE CITATION Sheet 1 of 2			Attorney Dock 02973.000			Serial No. TBA	922 922			
			Applicant(s): Thanos H	IALAZONET	TIS et al.					
			Filing Date: Herewith	Filing Date: Herewith			600			
	T DOCUMENTS					_	07			
Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing D				
FOREIGN F	ATENT DOCUMEN	TTS								
Examiner	Document No.	Date	Country Class Su		Subclass	Translation				
Initial						YES	NO			
214	94/08241	4/1994	WO							
277	95/17213	6/1995	WO							
534	0 518 650	12/1992	EP							
557	94/12202	1994	WO		 					
357	94/10306	5/1994	WO		-					
OTHER DO	CUMENTS (includin	g Author, Title, Date,	Pertinent Pages, etc.)		· · · · · · · · · · · · · · · · · ·					
50M	Coller et al., "Substituting Isoserine for Serine in the Thrombin Receptor Activation Peptide SFLLRN Confers Resistance to Aminopeptidase M-induced Cleavage and Inactivation," J. Biol. Chem, 268(28):20741-20743 (1993)									
554	Couder et al., "Synthesis and Biological Activities of ψ(CH ₂ NH) Pseudopeptide Analogues of the C-terminal Hexapeptide of Neurotensin," <i>Internat. J. Peptide & Protein Res.</i> , 41(2):181-184 (1993)									
SOU	DalPozzo et al., "H-Gly-Hisψ(NHCO)Lys-OH, Partially Modified Retro-Inverso Analogue of the Growth Factor Glycyl-L-histidyl-l-lysine with Enhanced enzymatic Stability," Int. J. Peptide Protein Res., 41:561-566 (1993)									
65th	Hupp et al., "Regulation of the Cryptic Sequence-Specific DNA-Binding Function of p53 by Protein Kinases," Cold Spring Harbor Symposia on Quantitative Biology, Vol. LIX, pp. 195-205 (1994)									
Sight	Hupp et al, "Small Peptides Activate the Latent Sequence-Specific DNA Binding Function of p53," Cell, 83:237-245 (1995)									
50H	Shaw et al., "Regulation of Specific DNA Binding by p53: Evidence for a Role of o-Glycosylation and Charged Residues at the Carboxy-terminus," <i>Oncogene</i> , 12:921-930 (1996)									
304	Takenaka et al., "Regulation of the Sequence-Specific DNA Binding Function of p53 by Protein Kinase C and Protein Phosphatases," J. Biol. Chem., 270(10):5405-5411 (1995)									
2024	Tanigaki et al., "The Peptide Binding Specificity of HLA-B27 Subtypes," Immunogenetics, 40:192-198 (1994)									
Soul	Powell et al., "Peptide Stability in Drug Development. II. Effect of Single Amino acid Substitution and Glysosylation on Peptide Reactivity in Human Serum," <i>Pharmaceutical Research</i> , 10(9):1268-1273 (1993)									
	Brady et al., "Reflections on a Peptide," Nature, 368:692-693 (1994)									
	Hupp et al., Allosteric Activation of Latent p53 Tetramers," Current Biology, 4(10):865-875 (1994)									
500	Wade-Evans et al., "Precise Epitope Mapping of the Murine Transformation-Associated Protein, p53," EMBO J., 4"699-706 (1985)									
	Finlay et al., "The p53 Proto-Oncogene Can Act as a Suppressor of Transformation," Cell, 57:1083-1093 (1989)									
	Soussi et al., "Structural Aspects of the p53 Protein in Relation to Gene Evolution," Oncogene, 5:945-952 (1990)									
	Hupp et al., "Regulation of the Specific DNA Binding Function of p53," Cell, 71:857-886 (1992)									
21	· · · · · · · · · · · · · · · · · · ·		sideration in the Design of			es," <i>Biope</i>	olymers,			

No.

					^д ~					
USPTO Form 1449 Patent and Tradema	U.S. Department of Commerce rk Office	Attorney Docket N 02973.00031	0.	Serial No. TBA	2992					
	TION DISCLOSURE CITATION	Applicant(s): Thanos HALAZONETIS et al.								
Sheet I of 2		Filing Date: Herewith		Group:	48					
SOH	Hupp et al., "Activation of the Cryptic DNA Binding Function of Mutant Forms of p53," Nucleic Acids Res., 21:3167= 3174 (1993)									
STA	Fujiwara et al., "A Retroviral Wild-Type p53 Expression Vector Penetrates Human Lung Cancer Spheroids and Inhibits Growth by Inducing Apoptosis," Cancer Res., 53:4129-4133 (1993)									
SIM	Halazonetis et al., "Wild-Type p53 Adopts a 'Mutant'-like Conformation when Bound to DNA," EMBO J., 12:1021-1028 (1993)									
SSM	Halazonetis et al., "Conformational Shifts Propagate from the Oligomerization Domain of p53 to its Tetrameric DNA Finding Domain and Restore DNA Binding to Select p53 Mutants," <i>EMBO J.</i> , 12:5057-5064 (1993)									
354 514	Bugg et al., "Drugs by Design," Sci. Am., 269:92-98 (1993)									
STU	Friend, "p53: A Glimpse at the Puppet Behind the Shadow Play," Science, 265:334-335 (1994)									
SSM	Cho et al., "Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations," Science, 265:346-355 (1994)									
SOH	Clore et al., "High Resolution Structure of the Oligomerization Domain of p53 by Multidimensional NMR," Science, 265:386-391 (1994)									
SIM	Speir et al., "Potential Role of Human Cytomegalovirus and p53 Interaction in Coronary Restenosis," Science, 265:391-394 (1994)									
254	Cox et al., "Xenopus p53 is Biochemically Similar to the Human Tumour Suppressor Protein p53 and is Induced upon DNA Damage in Somatic Cells," Oncogene, 9:2951-2959 (1994)									
501	Jameson et al., "A Rationally Designed CD4 Analogue Inhibits Experimental Allergic Encephalomyelitis," <i>Nature</i> , 368-744-7,46 (1994)									
551	Moore, "Designing Peptide Mimetics," Trends Pharmacol. Sci., 15:124-129 (1994)									
SH	Dean, "Recent Advances in Drug Design Methods" Where Will They Lead?" BioEssays, 16:683-687 (1994)									
501	Naoko Arai et al., "Immunologically Distinct p53 Molecules Generated by Alternative Splicing," Molecular and Cellular Biology, Vol 6, No. 9, September 1986, p. 3232-3239									
SSH	Stryer. Biochemistry Second Edition, p. 13-17									
EXAMINER *EXAMINER: Initia	Mulh	600 Draw line through district if the in-	DATE CONSIDERED	03						
*EXAMINER: Initial if reference considered, whether or noticitation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.										

**Copies of references not provided at the time of this submission.